skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Results 1 2 3 4 5 next page
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel
Material Type:
Article
Add to My Research

Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel

The oncologist (Dayton, Ohio), 2022-09, Vol.27 (9), p.722-731 [Peer Reviewed Journal]

The Author(s) 2022. Published by Oxford University Press. ;COPYRIGHT 2022 Oxford University Press ;The Author(s) 2022. Published by Oxford University Press. 2022 ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyac101 ;PMID: 35704278

Full text available

2
Breast Awareness, Self‐Reported Abnormalities, and Breast Cancer in Rural Ethiopia: A Survey of 7,573 Women and Predictions of the National Burden
Material Type:
Article
Add to My Research

Breast Awareness, Self‐Reported Abnormalities, and Breast Cancer in Rural Ethiopia: A Survey of 7,573 Women and Predictions of the National Burden

The oncologist (Dayton, Ohio), 2021-06, Vol.26 (6), p.e1009-e1017 [Peer Reviewed Journal]

2021 The Authors. published by Wiley Periodicals LLC on behalf of AlphaMed Press. ;2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. ;COPYRIGHT 2021 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1002/onco.13737 ;PMID: 33650727

Full text available

3
Affinity proteomics within rare diseases: a BIO‐NMD study for blood biomarkers of muscular dystrophies
Material Type:
Article
Add to My Research

Affinity proteomics within rare diseases: a BIO‐NMD study for blood biomarkers of muscular dystrophies

EMBO molecular medicine, 2014-07, Vol.6 (7), p.918-936 [Peer Reviewed Journal]

2014 The Authors. Published under the terms of the CC BY 4.0 license ;2014 The Authors. Published under the terms of the CC BY 4.0 license. ;COPYRIGHT 2014 John Wiley & Sons, Inc. ;2014. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;2014 The Authors. Published under the terms of the CC BY 4.0 license 2014 ;ISSN: 1757-4676 ;ISSN: 1757-4684 ;EISSN: 1757-4684 ;DOI: 10.15252/emmm.201303724 ;PMID: 24920607

Full text available

4
Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma
Material Type:
Article
Add to My Research

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma

The oncologist (Dayton, Ohio), 2023-03, Vol.28 (3), p.220-229 [Peer Reviewed Journal]

The Author(s) 2022. Published by Oxford University Press. 2022 ;The Author(s) 2022. Published by Oxford University Press. ;COPYRIGHT 2023 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyac249 ;PMID: 36562592

Full text available

5
Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem
Material Type:
Article
Add to My Research

Rethinking the nonprofit foundation: an emerging niche in the rare disease ecosystem

EMBO molecular medicine, 2017-09, Vol.9 (9), p.1179-1182 [Peer Reviewed Journal]

2017 Children's Tumor Foundation. Published under the terms of the CC BY 4.0 license ;COPYRIGHT 2017 John Wiley & Sons, Inc. ;2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1757-4676 ;EISSN: 1757-4684 ;DOI: 10.15252/emmm.201708203 ;PMID: 28743783

Full text available

6
The awesome lysosome
Material Type:
Article
Add to My Research

The awesome lysosome

EMBO molecular medicine, 2016-02, Vol.8 (2), p.73-76 [Peer Reviewed Journal]

2015 The Author. Published under the terms of the CC BY 4.0 license ;COPYRIGHT 2016 John Wiley & Sons, Inc. ;2016. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1757-4676 ;EISSN: 1757-4684 ;DOI: 10.15252/emmm.201505966 ;PMID: 26787653

Full text available

7
The location of splenic NKT cells favours their rapid activation by blood-borne antigen
Material Type:
Article
Add to My Research

The location of splenic NKT cells favours their rapid activation by blood-borne antigen

The EMBO journal, 2012-05, Vol.31 (10), p.2378-2390 [Peer Reviewed Journal]

Copyright © 2012 European Molecular Biology Organization ;Copyright © 2012, European Molecular Biology Organization 2012 European Molecular Biology Organization ;ISSN: 0261-4189 ;EISSN: 1460-2075 ;DOI: 10.1038/emboj.2012.87 ;PMID: 22505026 ;CODEN: EMJODG

Full text available

8
Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial
Material Type:
Article
Add to My Research

Combining Sunitinib and Bevacizumab for the Management of Advanced Renal Cell Carcinoma: A Phase I/II Trial

The oncologist (Dayton, Ohio), 2023-05, Vol.28 (5), p.e254-e262 [Peer Reviewed Journal]

The Author(s) 2023. Published by Oxford University Press. 2023 ;The Author(s) 2023. Published by Oxford University Press. ;COPYRIGHT 2023 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyac261 ;PMID: 36648325

Full text available

9
Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study
Material Type:
Article
Add to My Research

Utility of Low-Dose Duvelisib for Advanced Mycosis Fungoides: A Single-Institution Study

The oncologist (Dayton, Ohio), 2024-03, Vol.29 (3), p.272 [Peer Reviewed Journal]

COPYRIGHT 2024 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/onoolo/oyad345

Full text available

10
Calcineurin–NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy
Material Type:
Article
Add to My Research

Calcineurin–NFAT signalling in myeloid leucocytes: new prospects and pitfalls in immunosuppressive therapy

EMBO molecular medicine, 2017-08, Vol.9 (8), p.990-999 [Peer Reviewed Journal]

2017 The Authors. Published under the terms of the CC BY 4.0 license ;2017 The Authors. Published under the terms of the CC BY 4.0 license. ;COPYRIGHT 2017 John Wiley & Sons, Inc. ;2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1757-4676 ;EISSN: 1757-4684 ;DOI: 10.15252/emmm.201707698 ;PMID: 28606994

Full text available

11
Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
Material Type:
Article
Add to My Research

Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss

The oncologist (Dayton, Ohio), 2021-06, Vol.26 (6), p.e963-e970 [Peer Reviewed Journal]

2021 The Authors. published by Wiley Periodicals LLC on behalf of AlphaMed Press. ;2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. ;COPYRIGHT 2021 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1002/onco.13774 ;PMID: 33818860

Full text available

12
The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer
Material Type:
Article
Add to My Research

The Use of Natural Language Processing to Assess Social Support in Patients With Advanced Cancer

The oncologist (Dayton, Ohio), 2023-02, Vol.28 (2), p.165-171 [Peer Reviewed Journal]

The Author(s) 2022. Published by Oxford University Press. ;COPYRIGHT 2023 Oxford University Press ;The Author(s) 2022. Published by Oxford University Press. 2022 ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyac238 ;PMID: 36427022

Full text available

13
Diagnostic host gene signature for distinguishing enteric fever from other febrile diseases
Material Type:
Article
Add to My Research

Diagnostic host gene signature for distinguishing enteric fever from other febrile diseases

EMBO molecular medicine, 2019-10, Vol.11 (10), p.e10431-n/a [Peer Reviewed Journal]

2019 The Authors. Published under the terms of the CC BY 4.0 license ;2019 The Authors. Published under the terms of the CC BY 4.0 license. ;COPYRIGHT 2019 John Wiley & Sons, Inc. ;2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1757-4676 ;EISSN: 1757-4684 ;DOI: 10.15252/emmm.201910431 ;PMID: 31468702

Full text available

14
Transcriptional response to hepatitis C virus infection and interferon‐alpha treatment in the human liver
Material Type:
Article
Add to My Research

Transcriptional response to hepatitis C virus infection and interferon‐alpha treatment in the human liver

EMBO molecular medicine, 2017-06, Vol.9 (6), p.816-834 [Peer Reviewed Journal]

2017 The Authors. Published under the terms of the CC BY 4.0 license ;2017 The Authors. Published under the terms of the CC BY 4.0 license. ;COPYRIGHT 2017 John Wiley & Sons, Inc. ;2017. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;Distributed under a Creative Commons Attribution 4.0 International License ;ISSN: 1757-4676 ;EISSN: 1757-4684 ;DOI: 10.15252/emmm.201607006 ;PMID: 28360091

Full text available

15
Phase I Study of Afatinib and Selumetinib in Patients with KRAS‐Mutated Colorectal, Non‐Small Cell Lung, and Pancreatic Cancer
Material Type:
Article
Add to My Research

Phase I Study of Afatinib and Selumetinib in Patients with KRAS‐Mutated Colorectal, Non‐Small Cell Lung, and Pancreatic Cancer

The oncologist (Dayton, Ohio), 2021-04, Vol.26 (4), p.290-e545 [Peer Reviewed Journal]

AlphaMed Press; the data published online to support this summary are the property of the authors. ;COPYRIGHT 2021 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1002/onco.13631 ;PMID: 33296125

Full text available

16
Safety and Efficacy of Cetuximab‐Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer
Material Type:
Article
Add to My Research

Safety and Efficacy of Cetuximab‐Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer

The oncologist (Dayton, Ohio), 2021-06, Vol.26 (6), p.e1018-e1035 [Peer Reviewed Journal]

2021 AlphaMed Press. ;COPYRIGHT 2021 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1002/onco.13754 ;PMID: 33751752

Full text available

17
Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer
Material Type:
Article
Add to My Research

Patient Blood Type Is Associated With Response to Immune Checkpoint Blockade in Metastatic Cancer

The oncologist (Dayton, Ohio), 2022-09, Vol.27 (9), p.e739-e747 [Peer Reviewed Journal]

COPYRIGHT 2022 Oxford University Press ;The Author(s) 2022. Published by Oxford University Press. 2022 ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyac128 ;PMID: 35816018

Full text available

18
The Use of Wearable Devices in Oncology Patients: A Systematic Review
Material Type:
Article
Add to My Research

The Use of Wearable Devices in Oncology Patients: A Systematic Review

The oncologist (Dayton, Ohio), 2024-04, Vol.29 (4), p.e419-e430 [Peer Reviewed Journal]

The Author(s) 2023. Published by Oxford University Press. ;COPYRIGHT 2024 Oxford University Press ;The Author(s) 2023. Published by Oxford University Press. 2023 ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1093/oncolo/oyad305 ;PMID: 37971410

Full text available

19
A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)
Material Type:
Article
Add to My Research

A Phase II Study of Apatinib in Patients with Chemotherapy‐Refractory Esophageal Squamous Cell Carcinoma (ESO‐Shanghai 11)

The oncologist (Dayton, Ohio), 2021-06, Vol.26 (6), p.e925-e935 [Peer Reviewed Journal]

2021 The Authors. published by Wiley Periodicals LLC on behalf of AlphaMed Press. ;2021 The Authors. The Oncologist published by Wiley Periodicals LLC on behalf of AlphaMed Press. ;COPYRIGHT 2021 Oxford University Press ;ISSN: 1083-7159 ;EISSN: 1549-490X ;DOI: 10.1002/onco.13668 ;PMID: 33393167

Full text available

20
miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC
Material Type:
Article
Add to My Research

miR‐9 modulates and predicts the response to radiotherapy and EGFR inhibition in HNSCC

EMBO molecular medicine, 2021-07, Vol.13 (7), p.n/a [Peer Reviewed Journal]

2021 The Authors. Published under the terms of the CC BY 4.0 license ;COPYRIGHT 2021 John Wiley & Sons, Inc. ;2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. ;ISSN: 1757-4676 ;EISSN: 1757-4684 ;DOI: 10.15252/emmm.202012872 ;PMID: 34062049

Full text available

Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
  1. Before 2014  (2)
  2. 2014 To 2016  (6)
  3. 2017 To 2019  (7)
  4. 2020 To 2022  (66)
  5. After 2022  (31)
  6. More options open sub menu

Searching Remote Databases, Please Wait